The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...

Aspirational adenoma detection rate should be 20%. Where polyp detection rate can be shown to be accurate ... for confusion if there is more than one set of tattoos in the colon. 100% of patients with ...

A 75-year-old man was referred for the endoscopic management of an 80 mm large non-pedunculated colorectal polyp (LNPCP) in the sigmoid colon. The lesion was evaluated ... consistent with benign ...

When this is done there is little serious opposition to the notion that adenomatous polyps have rarely, if ever, been proved to harbor invasive or metastasizing carcinoma, and that villous ...

Both Jayne Torvill and Christopher Dean announced they will retire at the end of the year and will leave their roles as head judges on Dancing on Ice.

Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...

If a person has a type of noncancerous polyp called an adenomatous polyp, they have an increased risk of developing colon cancer. These polyps form on the inner walls of the large intestine.

Familial adenomatous polyposis (FAP ... serve as proof of principle that once we have insight into what drives pre-malignant polyps toward adenomas and ultimately colon cancer, we can strategize ways ...